Agenus

Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer.

[Agenus @Agenus_Bio]

A few great days in Chicago at #ASCO2026 connecting with IO experts, attending scientific sessions and reconnecting with colleagues across the oncology community.

We return energized and ready to get back to work advancing IO for patients.

visit: https://t.co/2rRKa6w2xG

[Agenus @Agenus_Bio]

At #ASCO26, Agenus + Noetik will present retrospective data on TARIO-2, an AI model analyzing routine H&E images from BOT+BAL-treated pts.

In refractory MSS mCRC NLM, the AI-identified subgroup had 64% response vs 9% in the remaining cohort.
Full release: https://t.co/kqD3gNHdhv

[Agenus @Agenus_Bio]

New Phase 2 #BOT+BAL melanoma data will be presented at #ASCO26.

In heavily pretreated advanced checkpoint-refractory #melanoma, median OS was 16.6 months, 42% of patients were alive at 2 years, and median DOR was not reached.

Read the Release: https://t.co/kqD3gNHdhv

[MiNK Therapeutics @MiNK_iNKT]

At #ASGCT2026, MiNK is presenting clinical evidence that agenT-797, our off-the-shelf allogeneic #iNKT cell therapy, generated distinct immune responses in solid tumors and #ARDS.

The data support the potential of iNKT cells to drive context-dependent immune reprogramming.

Read more: https://t.co/JEtcHAWLQX

[MiNK Therapeutics @MiNK_iNKT]

MiNK and First Lviv Territorial Medical Union have initiated a randomized Phase 2 trial evaluating agenT-797 in severe acute lung injury and critical illness.

The study will assess clinically meaningful ICU outcomes, including survival, ventilator-free days, recovery and secondary infections.

Read more: https://t.co/JEtcHAWLQX

$INKT #ARDS #CellTherapy #CriticalCare

[MiNK Therapeutics @MiNK_iNKT]

🫁 Today - 11am at #ATS2026, Dr. Terese Hammond presents new findings involving the combination of agenT-797 (@MiNK_iNKT) + Anktiva® (N-803) (@ImmunityBio) in persistent pulmonary fungal infection under complex pathogenic conditions.

#Pulmonary #CriticalCare #ARDS #Immunotherapy #CellTherapy

[Jennifer Buell @jbuell01]

🫁 Severe inflammatory lung disease driven by deadly pathogens and other fibrotic events is becoming an increasingly urgent global challenge in pulmonary medicine.

Today at #ATS2026, Dr. Terese Hammond presents @MiNK_iNKT agenT-797 + @ImmunityBio Anktiva® data under complex pathogenic conditions. #iNKT #pulmonary #ARDS #sepsis #Hantavirüs #fungemia

[Agenus @Agenus_Bio]

We will report Q1 2026 financial results before market open on Mon, May 11.

A June webcast, held with our Annual Meeting of Shareholders, will spotlight strategic priorities, data milestones and progress across the global BOT/BAL program.

Read Release: https://t.co/kqD3gNHL73

[Agenus @Agenus_Bio]

Agenus is heading to #ASCO2026 with 4 accepted abstracts, including the first Phase 2 presentation of #BOT+/-BAL in advanced cutaneous #melanoma, plus #CRC and translational research updates.
Read press release: https://t.co/kqD3gNHL73
$AGEN #immunotherapy #biotech

[Agenus @Agenus_Bio]

Agenus and BAP Pharma announced an exclusive global partnership supporting authorized access programs for investigational BOT+BAL, including France’s AAC pathway and named-patient programs in select countries.
Read release:https://t.co/kqD3gNHL73

[Agenus @Agenus_Bio]

Our updated April 2026 corporate overview is now available, highlighting BOT+BAL #CRC progress, Phase 3 BATTMAN rationale, expansion potential, and key 2026 catalysts.
Visit our IR site: https://t.co/k0yvSc5TIG
View the deck: https://t.co/rx73UvWF1Q
$AGEN #Immunotherapy

[MiNK Therapeutics @MiNK_iNKT]

MiNK is live in Los Angeles for #AACRIO25.

Tune in later today to hear new translational data from the ongoing Ph2 study evaluating allo-iNKTs (agenT-797) in combination with @Agenus_Bio's BOT/BAL & chemotherapy in refractory #GastricCancer.

Learn more: https://t.co/xZPYTY3xb4

[MiNK Therapeutics @MiNK_iNKT]

MiNK Therapeutics announces abstract acceptance at American Thoracic Society (ATS) International Conference 2026 Featuring #agenT-797 in a novel combo approach for persistent infection—highlighting the potential of iNKT cell therapy beyond oncology.📍

Poster #103 | May 20
Details: https://t.co/JEtcHAXjGv

#ATS2026 #Immunotherapy #CellTherapy

[Agenus @Agenus_Bio]

Agenus announces data from a Phase II investigator sponsored trial of #BOT/BAL + @MiNK_iNKT agenT-797 in PD-1 refractory gastroesophageal cancer.

🔹Apr 20
🔹2–5 PM PT
🔹Poster 52 | CT166
#AACR25 #Immunotherapy #Oncology

[Agenus @Agenus_Bio]

First patient enrolled in our global Phase 3 #BATTMAN trial evaluating #BOT+BAL in MSS/pMMR mCRC — a population historically resistant to immunotherapy.

A key step forward as we advance our registrational program.

🔗https://t.co/kqD3gNHL73

#Oncology #Immunotherapy $AGEN

[Agenus @Agenus_Bio]

We’re live.

Join now for updates on #BOT+BAL, #access programs, and 2026 priorities.

▶️ Watch: https://t.co/gE3yssC3bi

#immunotherapy #CRC #innovation

[Agenus @Agenus_Bio]

Reminder: Join our March Stakeholder Webcast today.

Updates on #BOT+BAL, global #access, and 2026 priorities.

Register: https://t.co/gE3yssC3bi
Submit Questions: https://t.co/euZklBusdl

[Agenus @Agenus_Bio]

March is Colorectal Cancer Awareness Month.

But for patients, the need for better options doesn’t end on March 31.

Our focus continues on advancing #immunotherapy for those with the fewest options.

#CRCAwarenessMonth #innovation

[Agenus @Agenus_Bio]

Agenus announces March webcast on Tues, Mar 31st at 4:30EST

Updates on:
• Clinical progress
• Global access (France AAC + NPP)
• 2026 priorities
Live Q&A included.
Register: https://t.co/gE3yssCB0Q
Submit questions: https://t.co/euZklBv02T

#Immunotherapy #Oncology #BOT

[Agenus @Agenus_Bio]

At Agenus, we believe innovation should confront tumors historically resistant to #immunotherapy
and real progress means moving beyond incremental benefit.

#CRCAwarenessMonth #UnmetNeed #Innovation